Compare IMVT & POST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | POST |
|---|---|---|
| Founded | 2018 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.1B |
| IPO Year | N/A | N/A |
| Metric | IMVT | POST |
|---|---|---|
| Price | $24.22 | $104.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $29.13 | ★ $125.33 |
| AVG Volume (30 Days) | ★ 1.4M | 794.9K |
| Earning Date | 02-06-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.51 |
| Revenue | N/A | ★ $8,158,100,000.00 |
| Revenue This Year | N/A | $5.13 |
| Revenue Next Year | N/A | $0.40 |
| P/E Ratio | ★ N/A | $18.96 |
| Revenue Growth | N/A | ★ 2.97 |
| 52 Week Low | $12.72 | $95.07 |
| 52 Week High | $27.80 | $119.85 |
| Indicator | IMVT | POST |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 64.82 |
| Support Level | $25.42 | $100.09 |
| Resistance Level | $26.82 | $100.02 |
| Average True Range (ATR) | 1.11 | 2.87 |
| MACD | -0.27 | 0.77 |
| Stochastic Oscillator | 1.84 | 69.26 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Post Holdings Inc. is a consumer packaged goods holding company with products sold through grocery, club, and drug stores, mass merchandisers, foodservice, food ingredient, and eCommerce. It operates through four reportable segments: Post Consumer Brands, focused on North American ready-to-eat cereal and granola, pet food, and nut butters; Weetabix, focused on U.K. ready-to-eat cereal, muesli, and protein-based shakes; Foodservice, focused on egg and potato products; and Refrigerated Retail, focused on side dish, egg, cheese, and sausage products. Products are sold across channels, including retailers, wholesalers, convenience stores, pet supply retailers, drug store customers, military and national restaurant chains, with revenues largely generated in the U.S.